
Accuray Incorporated
NASDAQ•ARAY
CEO: Ms. Suzanne Winter M.B.A.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2007-02-08
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Contact Information
Market Cap
$92.46M
P/E (TTM)
-5.0
33.6
Dividend Yield
--
52W High
$2.95
52W Low
$0.78
52W Range
Rank68Top 98.2%
1.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$93.94M-7.49%
4-Quarter Trend
EPS
-$0.18+355.70%
4-Quarter Trend
FCF
$8.36M-199.31%
4-Quarter Trend
2026 Q1 Earnings Highlights
Key Highlights
Service Revenue Increased Services revenue reached $56.8M USD for the quarter, marking a 7% increase compared to prior year period.
Product Sales Decreased Product revenue fell sharply to $37.2M USD, a 23% decrease driven by lower shipments volume to China.
Positive Operating Cash Flow Net cash provided by operating activities totaled $12.2M USD for the three months ended September 30, 2025.
Strategic Transformation Announced Company announced major organizational transformation in October 2025, appointing Stephen La Neve as new CEO.
Risk Factors
Macroeconomic Headwinds Persist Inflation, supply chain issues, and logistics costs expected to adversely affect gross margins through at least fiscal year 2026.
China Sales Volume Impacted Uncertainty regarding U.S.-China trade tariffs expected to decrease China sales volume through at least first half fiscal 2026.
Deteriorating Profitability Metrics Gross profit dropped 23% to $26.5M USD; net loss widened to $(21.7M) USD for the quarter.
Debt Covenants Compliance Risk Compliance with Financing Agreement covenants depends on future performance; failure risks debt acceleration and foreclosure.
Outlook
Liquidity Position Adequate Current cash balance and debt facilities sufficient to fund operations for at least the next twelve months period.
Restructuring Cost Accrual Recorded $1.5M restructuring charge for workforce reduction; remaining accrual of $1.9M expected to be paid in fiscal 2026.
New Financing Agreement Secured new five-year Financing Agreement providing $150M term loan and $20M delayed draw facility in June 2025.
Tax Law Changes Evaluation Evaluating impact of new federal tax legislation enacted July 2025, including changes to R&D expense capitalization rules.
Peer Comparison
Revenue (TTM)
ARAY$450.90M
$76.05M
RCEL$72.40M
Gross Margin (Latest Quarter)
MXCT92.4%
86.4%
83.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| SGHT | $318.29M | -6.8 | -61.6% | 35.0% |
| PROF | $240.41M | -6.0 | -86.8% | 0.7% |
| RPID | $182.61M | -4.1 | -73.9% | 28.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-6.8%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Feb 4, 2026
EPS:-$0.11
|Revenue:$100.86M
Reports
All Years
Form 10-Q - Q1 2026
Period End: Sep 30, 2025|Filed: Nov 5, 2025|Revenue: $93.94M-7.5%|EPS: $-0.18+355.7%MissForm 10-K - FY 2025
Period End: Jun 30, 2025|Filed: Aug 28, 2025|Revenue: $458.51M+2.7%|EPS: $-0.02+90.3%MissForm 10-Q - Q3 2025
Period End: Mar 31, 2025|Filed: May 2, 2025|Revenue: $113.24M+12.0%|EPS: $-0.01-80.3%BeatForm 10-Q - Q2 2025
Period End: Dec 31, 2024|Filed: Feb 5, 2025|Revenue: $116.17M+8.3%|EPS: $0.03-125.4%BeatForm 10-Q - Q1 2025
Period End: Sep 30, 2024|Filed: Nov 6, 2024|Revenue: $101.55M-2.3%|EPS: $-0.04+28.7%BeatForm 10-K - FY 2024
Period End: Jun 30, 2024|Filed: Sep 19, 2024|Revenue: $446.55M-0.2%|EPS: $-0.16-63.6%MissForm 10-Q - Q3 2024
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $101.13M-14.3%|EPS: $-0.06-1114.3%MissForm 10-Q - Q2 2024
Period End: Dec 31, 2023|Filed: Feb 7, 2024|Revenue: $107.24M-6.6%|EPS: $-0.10+397.0%Miss